Patent · US Active

Buffers for stabilization of lentiviral preparations

US10724006B2 · kind B2 · utility

0Cited by

0References

23Claims

0Family size

Assignees

Novartis AG · CH
The Trustees of the University of Pennsylvania · US

Inventors

Amitabha Deb · Cambridge, US
Eugene Nebelitsky · Norwood, US
Vladimir Slepushkin · Everett, US

Key dates

Filing date	Nov 18, 2016
Grant date	Jul 28, 2020
Priority date	—
Expiry date	Nov 18, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2740/16051
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides lentiviral preparations containing a sulfonic acid buffer, such as 1,4-piperazinediethanesulfonic acid (PIPES), 2-(N-morpholino)ethanesulfonic acid (MES), and 3-morpholinopropane-1-sulfonic acid (MOPS), a sodium citrate buffer, or a phosphate buffer. The invention additionally encompasses methods of lentiviral purification as well as methods of transducing human cells.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.